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Background: Patients with Chronic Heart Failure (CHF) develop similar symptoms of exertional
breathlessness and fatigue as patients with COPD. Although pulmonary (exercise based) reha-
bilitation (PR) is an integral part of the management of COPD, the potential for exercise reha-
bilitation (ER) to assist patients with CHF may not be as readily appreciated. We investigated
whether combined ER for patients with CHF and COPD was feasible and effective using the
model of PR.
Methods: 57 patients with CHF were randomized 2:1 to 7 weeks ER (CHF-ER) or 7 weeks of
usual care (CHF-UC). As a comparator 55 patients with COPD were simultaneously recruited
to the same ER program (COPD-ER). The primary outcome measure was the Incremental
Shuttle Walk Test (ISWT) and the secondary outcome measures were the Endurance Shuttle
Walk Test (ESWT), isometric quadriceps strength and health status.
Results: 27 CHF and 44 COPD patients completed ER and 17 patients with CHF completed UC.
The CHF-ER group made significant improvements, compared to CHF-UC, in the mean (95%CI)
ISWT distance; 62(35e89)m vs 6(11 to 33)m p < 0.001. The CHF-ER group also made statis-
tically significant improvements in health status. The improvements in exercise performance
and health status were similar between patients with CHF and COPD, treated with ER.
Conclusion: Patients with CHF who undergo ER improve similarly in their exercise performance
and health status to COPD. Combined training programs for COPD and CHF are effective and
feasible, such that service provision could be targeted around common disability rather than
the primary organ disease.
ª 2010 Elsevier Ltd. All rights reserved.16 2871471.
ail.com (R.A. Evans).
0 Elsevier Ltd. All rights reserved.
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4,25,26 and the pulmonaryChronic respiratory disease and cardiovascular disease are
two of the four priority non-communicable diseases for the
World Health Organisation. Cardiovascular disease and
Chronic Obstructive Pulmonary Disease are the first and
fifth leading causes of death worldwide and are in the ten
leading causes of burden of disease for all countries.1
Exertional breathlessness and fatigue are frequent
symptoms common to COPD and chronic heart failure
(CHF), which result in marked activity limitation
(disability).
In COPD and in CHF the degree of primary organ
impairment, as assessed by the FEV1 and left ventricular
ejection fraction (LVEF), respectively, correlates poorly
with exercise capacity.2,3 Both conditions also have in
common secondary impairments such as skeletal muscle
dysfunction4,5 which contribute substantially to exercise
intolerance6,7 and mortality.8e10 Deconditioning, systemic
inflammation and nutritional status have all been impli-
cated in the development of skeletal muscle dysfunction.5
In both conditions, skeletal muscle dysfunction is at
least partially reversible with exercise training.11,12 The
service of pulmonary rehabilitation (with exercise training
as a key component) is an integral part of the management
of patients with COPD.13 The model of pulmonary rehabil-
itation is symptom directed towards exertional dyspnea and
includes exercise training (individually prescribed lower
limb endurance training), multi-disciplinary education (e.g
exercise, energy conservation, relaxation, nutrition)
psychological support and self management.13e15 It is
‘designed to reduce symptoms, optimize functional status,
increase participation and reduce health care costs through
stabilizing or reversing the systemic manifestations of the
disease’14 and has a strong evidence base demonstrating
improvements in exercise performance and health
status.15,16
There is a substantial literature on the beneficial effects
of exercise training in CHF, including improvements in
exercise capacity,17 health status,18,19 and morbidity and
mortality.20 However, a practical exercise rehabilitation
service has not been integrated into the long-term
management of CHF, nearly to the extent that it has been
for COPD. Few studies have evaluated the influence of
exercise rehabilitation for CHF in a practical rehabilitation
setting.21 A large multicentre trial of exercise training in
CHF only resulted in modest short-term improvements in
exercise performance.22 This training intervention was not
part of a broader rehabilitation service, containing key
components of exercise, education, psychological support
and self management.
The traditional focus of cardiac rehabilitation (CR) is
aimed at the secondary prevention of cardiovascular
disease events, predominantly for patients after either
a myocardial infarction or cardiac surgery and currently
may exclude patients with CHF.23,24 The target population
for CR are frequently asymptomatic (NYHA class 1) with
preserved exercise tolerance.25 Many patients with CHF
would be unable to adhere to the absolute exercise
prescription set for CR. The symptoms and disability of
patients with CHF have more in common with COPD thanrehabilitation team are experienced in dealing with
patients with a reduced functional status. A symptom
directed programme (for both the exercise training and
education component) may be more suitable for patients
with CHF, and in practice these patients are increasingly
referred to pulmonary rehabilitation. In the US, recent
guidelines regarding outcome measures for CR excluded
patients with CHF,23 and a national audit in the UK
concluded that only a tiny fraction of patients with heart
failure receive rehabilitation.24
We hypothesized that a program of exercise rehabilita-
tion, supported by symptom based specific education,
could be successfully applied to patients with CHF in the
same setting as COPD. If successful this would provide
a generic, symptom based exercise rehabilitation program
for exertional dyspnea.
We therefore designed a randomized controlled trial of
supervized exercise rehabilitation compared to usual care
in patients with CHF and a comparative observational study
of the same exercise rehabilitation program between CHF
and COPD. The aim was to investigate whether patients
with CHF could improve their exercise performance and
health related quality of life with pulmonary rehabilitation
compared to usual care and whether the changes were
comparable to patients with COPD.
Methods
The study protocol was approved by the Leicestershire
Research Ethics Council (National Research Registry
N0123134233 - www.nrr.nhs.uk).
Participants
Chronic obstructive pulmonary disease (COPD)
Patients with a clinical diagnosis COPD, supporting
spirometry of an FEV1/FVC <70% and an FEV1 <80% pre-
dicted and MRC dyspnea scale 2e5 were eligible to partic-
ipate. Patients with COPD were consecutively recruited
from physician referrals to PR. Patients with known co-
morbid CHF were excluded.
Chronic heart failure (CHF)
Patients with a clinical diagnosis of CHF,27 New York Heart
Asscociation (NYHA) class IIeIV and evidence of left
ventricular dysfunction (LVEF) on echocardiography, were
eligible to participate. Patients were recruited from
community chronic heart failure nurses and had originally
been diagnosed by a cardiologist. Patients with known
COPD, FEV1/FVC <70% and FEV1 <80% and other respiratory
conditions were excluded.
All participants
Any medications relating to COPD or CHF were unchanged
during the trial. Patients with a predominant neurological,
locomotor or peripheral vascular limitation to exercise
were excluded. Patients within three months of an acute
myocardial infarction or with significant aortic stenosis
were excluded. All patients completed an incremental
cardiopulmonary exercise test to exclude any significant
Integrating patients with COPD and heart failure 1475arrhythmias or ischaemia, as per the American College of
Sports Medicine guidelines.28 Written consent was obtained.
Randomization and intervention
Exercise rehabilitation
We used an existing outpatient pulmonary (exercise)
rehabilitation (ER) program designed for patients with
COPD13e15 and previously described.29,30 This seven week
program involved supervized physical training twice weekly
for 2 h, which combined endurance training and patient
education by a multi-disciplinary team, with unsupervized
daily home training. Walking was the main training modality
and was individually prescribed at a speed equivalent to
85% VO2 peak derived from the Incremental Shuttle Walk
Test (ISWT).31 The initial duration of the walk was set from
the distance achieved on the ESWT. The duration of the
walk was increased throughout the seven weeks based on
the symptom of dyspnea, aiming for a Borg Scale breath-
lessness score of 3e6 at the end of exercise.
Peripheral muscle exercises were performed three times
a week using free weights for the upper limbs, and condi-
tioning exercises for the lower limbs; once at hospital and
twice at home. Four different exercises of ten repetitions
each were performed for both the upper and lower limbs.
Patients from both groups trained together and were
supervized by the same therapists. Completers were
defined has having attended twelve sessions. The education
component of the program was delivered identically to
both groups.
At least one of the rehabilitation team members present
in the exercise classes were trained in Advanced Life
Support and all were educated about the symptoms and
signs associated with the decompensation of heart failure
similar to understanding an exacerbation of COPD.
Usual care
The usual care group received only their usual care for
seven weeks.
Assignment
Patients with CHF were randomized to receive exercise
rehabilitation (CHF-ER) or usual care (CHF-UC) in a ratio of
2:1 ER to UC after completion of all baseline measure-
ments. This was to allow for a likely higher dropout among
the exercising group. The randomization was undertaken by
an outside institute and performed in blocks of four.
Treatment allocation was concealed by an outside
researcher. All patients with COPD were allocated to
receive the exercise rehabilitation program (COPD-ER).
Outcomes measures
The following outcome measures were performed at base-
line and after the intervention in all subjects and included
those used practically to assess the service.
Primary outcome measure
The primary outcome measure was the ISWT distance. The
ISWT is a maximal, externally paced, symptom limited testconducted along a 10m course.32 The ISWT has been vali-
dated both in patients with CHF33 and with COPD.34 It is
reproducible after one practice test.32,35 A familiarization
test was performed for both the ISWT and Endurance
Shuttle Walk Test (ESWT). The patients allocated to ER had
serial ISWTs at sessions 1, 4, 7, 11, and 14.
Secondary outcome measures
The Endurance Shuttle Walk Test (ESWT) is a measure of
submaximal exercise capacity. It has been validated in
COPD and is reproducible after familiarization.31 Isometric
quadriceps strength was measured using a Cybex II
dynamometer at 70. Six maximal voluntary contractions
(MVC) were performed and the peak torque (PT) taken as
the highest of the six. Body composition was measured by
bioelectrical impedance (Biostat 1500).36,37 The disease
specific questionnaires, used were the Chronic Heart
Questionnaire (CHQ)38 for CHF and the Chronic Respiratory
Questionnaire (CRQ)39 for COPD. These two questionnaires
comprise of the same four domains (dyspnea, fatigue,
emotional function and mastery) and were designed by the
same research group. The test operator was blinded to the
diagnostic category (COPD or CHF) and for the CHF pop-
ulation, the operator was unaware of the group allocation
(study or control) for the ISWT and ESWT.
Sample size calculation for the randomized
controlled trial
In order to show a 50 m difference in the change in ISWT
performance between the two groups and assuming a stan-
dard deviation (SD) of the change in ISWT of 50 m with 80%
power at the 5% level of significance 17 patients were
needed for each group.40 Patients with COPD and patients
with CHF were recruited simultaneously, so that training of
both groups could occur at the same time.
Statistical analysis
Appropriate parametric and non-parametric tests were
performed for the baseline intergroup differences. An
intention to treat (ITT) analysis was applied for the primary
outcome measure for the RCT and thereafter an efficacy
subset analysis (ESA) for completers was performed to
allow a direct comparison with the COPD group. Effect size
was calculated by (m1m2)/s where m1 and m2 Z mean of
each group and s the SD of the s mean of the two groups.
ANCOVA was performed to compare the change in outcome
measures between COPD-ER and CHF-ER accounting for any
difference in baseline variables. A MANOVA with Pillai’s
trace was performed for a comparison between COPD-ER
and CHF-ER for the serial ISWTs. Significance was set at
p < 0.05. Analyses were performed using SPSS version 14.0.
Results
Fig. 1 demonstrates the patient flow through the trial. 57
patients with CHF were randomized; 37 to exercise reha-
bilitation (ER) and 20 to usual care (UC). The majority of
patients with CHF had ischaemic cardiomyopathy (79%). 55
patients with COPD were recruited. There were no baseline
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between the CHF patients randomized to the intervention
or usual care groups (Table 1). All groups showed a similar
exercise performance and quadriceps muscle strength.
There were no significant adverse events during the exer-
cise tests. Baseline disease specific health status was
similar between the two CHF groups. The COPD subjects
had worse dyspnea and mastery scores, than those with
CHF (Table 1).
Results of exercise rehabilitation vs. usual care
in CHF
27 patients completed exercise rehabilitation and 17
patients completed usual care. Of the ten CHF-ER dropouts,
six attended only the first session of ER. These patients and
the three dropouts from the UC group were assigned a zero
score for the change in ISWT. The four dropouts during ER at
session four were assigned their last ISWT as their final
measurement. The CHF-ER group made a significant mean
(95%CI) improvement in ISWT of 45 (23e66) m p < 0.001
while the ISWT in the CHF-UC group remained the same 5
(9 to 19) m p Z 0.460. The intergroup mean (95%CI)
difference in the change in the ISWT was also statistically
significant 50 (25e76) m p < 0.001 d Z 0.51 (moderate
effect size). There was no statistically significant change in
any auxillary measurement at the end of the ISWT perfor-
mance, with ER or UC.Figure 1 Flow diagram of the RCT for CHF.Table 2 and Fig. 2 show the efficacy subset analysis for
all outcome measures and exercise performance respec-
tively. The CHF-ER group made significant improvements in
ESWT time compared to CHF-UC. The CHF-ER group made
statistically significant improvements in all four domains of
the CHQ compared to no change in any domain for the CHF-
UC group, but the between group difference did not reach
significance (Table 2). However, there was a between group
difference in the change in functional status (NYHA class)
between the CHF-ER and CHF-UC groups (Table 2).
There were a higher proportion of dropouts in the CHF-
ER group than the CHF-UC group 27% vs 15% respectively
(p Z 0.30). The number due to decompensation of heart
failure was similar; 2/37 for ER vs. 2/20 for UC. There were
more non-medical reasons for dropping out in the CHF-ER
group.
Results of exercise rehabilitation- COPD vs. CHF
44 patients with COPD completed ER. A similar proportion
of COPD patients (20%) dropped out compared to CHF (27%)
(p Z 0.43); 8 had medical reasons and 3 had non-medical
reasons.
The statistically significant improvements in ISWT and
ESWT for the CHF-ER group were similar to those with COPD
who underwent rehabilitation (Table 3). An ANCOVA for the
change in ISWT performance between COPD and CHF was
performed including baseline ISWT, FEV1% predicted and
BMI and there remained no difference between the two
groups (p Z 0.72). Patients with COPD could easily train
together with patients with CHF.
All patients had serial ISWT every 3rd or 4th session
throughout the seven weeks. 22/27 CHF and 36/44 COPD
had complete data sets for all five time points (Fig. 3).
There was no significant difference in the overall rate of
improvement between the two groups (pZ 0.07), although
patients with COPD experienced significant improvements
by session four (33m p < 0.001) whereas those with CHF did
not reach significance (16m p Z 0.19) at that stage. There
were no statistical differences in the ISWT performance
between the two groups at any session number.
Both exercise-trained groups made statistically signifi-
cant improvements in all four domains of the disease
specific questionnaire (Table 3). After an ANCOVA was
performed, accounting for the baseline scores, there was
no between group difference between the scores except
for a greater improvement in the fatigue score for COPD
(Table 3).
Discussion
This trial confirms that symptom-directed, exercise training
programs are feasible and effective for COPD and CHF and
that training can be progressed similarly for both cate-
gories, based on symptoms rather than diagnosis. Moreover,
there is a practical benefit to knowing that both groups
could train together, at the same time and location,
supervized by the same therapists.
Patients with CHF undergoing rehabilitation made highly
statistically significant improvements in exercise tolerance,
functional status and health status. This randomized study
Table 1 Baseline demographics, exercise performance and health status in CHF-UC, CHF-ER and COPD-ER groups.
CHF-UC n Z 20 CHF-ER n Z 37 COPD-ER n Z 55
Age (yrs) 73.2 (8.9) 69.8 (10.7) 69.1 (8.3)
Gender (% male) 70.0% 67.6% 54.5%
LVEF % 30.7 (12.7) 31.2 (8.4) N/A
FEV1/FVC 76.1 (4.7) 77.1 (4.7) 50.0 (8.7)
c
FEV1% predicted 82.2 (18.1) 81.2 (22.2) 42.9 (14.6)
c
Medication
ACE inhibitor/ATII antagonist 97% 90% N/A
Beta Blocker 81% 60%
NYHA Class for CHF or MRC dyspnea grade for COPD 2 (25%) 2 (46%) 2 (11%)
3 (65%) 3 (38%) 3 (48%)
4 (10%) 4 (16%) 4 (26%)
5 (15%)
BMI (kg/m2) 30.6 (6.5) 31.4 (6.4) 27.4 (5.2)c
FFMI (kg/m2) 19.0 (2.6) 19.9 (3.0) 17.1 (2.3)c
ISWT (m) 213 (91) 242 (154) 225 (114)
End heart rate (bpm) 102 (20) 98 (23) 107 (18)b
End oxygen saturation (%) 94 (3) 93 (6) 88 (8)b
End BSa 4.0 (3.0e6.0) 5.0 (3.5e5.0) 5.0 (4.0e7.0)
End PEa 15.0 (13.0e17.0) 15.0 (13.0e16.0) 15.0 (13.0e17.0)
ESWT (secs) 226 (93) 215 (83) 247 (154)
Quadriceps PT (Nm) 109 (39) 119 (53) 115 (44)
HRQL; CHQ or CRQ
Dyspnea (D) 3.73 (1.19) 3.57 (1.21) 2.43 (0.84)c
Fatigue (F) 3.25 (1.14) 3.40 (1.16) 3.25 (1.25)
Emotional Function (EF) 4.17 (1.29) 4.73 (1.32) 4.28 (1.20)
Mastery (M) 4.42 (1.18) 4.84 (1.17) 4.13 (1.18)b
Mean (SD) or % male.
LVEF e left ventricular ejection fraction, ACE e angiotensin converting enzyme inhibitor, ATII eangiotensin-II receptor antagonists,
NYHA- New York Heart Association, MRC e Medical Research Council, BMI e Body mass index, FFMI e fat free mass index,
ISWT e Incremental Shuttle Walk Test, ESWT e Endurance Shuttle Walk Test, PT e peak torque, HRQL e Health related quality of life,
CHQ e Chronic Heart Questionnaire, CRQ e Chronic Respiratory Questionnaire.
a median (IQ range) Borg Scale for breathlessness (BS) and perceived exertion (PE) N/A not applicable.
b p < 0.05 between COPD-ER and CHF-ER.
c p < 0.001 between COPD-ER and CHF-ER.
Integrating patients with COPD and heart failure 1477of pragmatic rehabilitation supports the benefit of exercise
training for CHF and adds to the current literature by
providing a successful model of rehabilitation for CHF.
Programs in pulmonary rehabilitation are able to also serveTable 2 Exercise rehabilitation (ER) versus usual care (UC) in C
Change in: CHF-ER p valueb CH
ISWT (m) 62 (35e89) <0.001 
ESWT (secs) 351 (203e498) <0.001 3
Quadriceps PT (Nm) 7 (0e13) 0.09 
HRQL (CHQ)
Dyspnea 0.65 (0.21e1.09) 0.01 0.1
Fatigue 0.39 (0.06e0.72) 0.02 0.1
Emotional Function 0.38 (0.01e0.75) <0.05 0.3
Mastery 0.36 (0.04e0.67) 0.03 0.0
NYHA classa 1 0.01 0
Mean (95% CI).
ISWT e Incremental Shuttle Walk Test, ESWT e Endurance Shuttle Wa
CHQ e Chronic Heart Questionnaire NYHA- New York Heart Associatio
a Median.
b Intragroup difference before and after the intervention.
c Intergroup difference between CHF-ER and CHF-UC.a population of patients with CHF who may not otherwise
be referred or have access to rehabilitation.
There is a growing appreciation of the similarity in the
systemic manifestations and disability between CHF andHF.
F-UC p valueb CHF-ER and CHF-UCc
6 (11 to 23) 0.47 <0.001 Effect size 0.57
6 (77 to 4) 0.08 <0.001 Effect size 0.95
2 (11 to 8) 0.75 0.19
4 (0.34 to 0.62) 0.55 0.12
6 (0.27 to 0.59) 0.44 0.37
8 (0.11 to 0.86) 0.12 1.00
8 (0.29 to 0.46) 0.64 0.26
0.32 0.02
lk Test, PT e peak torque, HRQL e Health related quality of life,
n.
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Figure 2 Results of the ISWT and ESWT for the RCT for CHF.
1478 R.A. Evans et al.COPD.41,42 Our study populations also had similar measures
of exercise performance, health status and quadriceps
strength. The peak heart rate on the ISWTwas lower in CHF
than in COPD, possibly because of beta blockade therapy in
CHF. Although treated as separate populations for the
purpose of this study, the two conditions often coexist
(20e39%).43,44 A recent report noted heart failure in
greater than 10% of patients with COPD undergoingTable 3 Exercise Rehabilitation in CHF and COPD.
Change in: CHF-ER p valueb
ISWT (m) 62 (35e89) <0.001
ESWT (secs) 351 (203e498) <0.001
Quadriceps PT (Nm) 7 (0e13) 0.09
HRQL (CHQ or CRQ)a
Dyspnea 0.65 (0.21e1.09) 0.01
ANCOVA 0.94
Fatigue 0.39 (0.06e0.72) 0.02
ANCOVA 0.46
Emotional Function 0.38 (0.01e0.75) 0.049
ANCOVA 0.50
Mastery 0.36 (0.04e0.67) 0.03
ANCOVA 0.55
Mean (95% CI).
ISWT e Incremental Shuttle Walk Test, ESWT e Endurance Shuttle Wa
CHQ e Chronic Heart Questionnaire.
a minimum important difference 0.5 units.
b Intragroup difference before and after ER.
c Intergroup difference between CHF-ER and COPD-ER.pulmonary rehabilitation45 and coexisting COPD in 18% of
patients post coronary artery bypass grafting (CABG)
undergoing cardiac rehabilitation.46 Although it is relatively
easy to exclude COPD from the CHF group, by spirometry,
CHF may be harder to exclude among patients with COPD as
standard tests, such as echocardiography, are technically
difficult in COPD47 and more invasive tests were not justi-
fiable for this trial. Co-existent disease has implications for
the current separate services of pulmonary and cardiac
rehabilitation.
We noted that training as a combined group did not
adversely affect the improvements for patients with COPD,
which remained similar to those previously reported.30,48
Although much of the literature for pulmonary rehabilita-
tion is for COPD there is an expanding group of other
chronic respiratory patients who may also gain benefit e.g
pulmonary fibrosis, bronchiectasis, cystic fibrosis, asthma
and pulmonary hypertension, and are being referred.15 The
PR population is becoming more heterogenous and there-
fore, a symptom based approach to exercise training
(rather than disease based) for patients with dyspnea,
would seem logical.
The pulmonary rehabilitation program was delivered
identically and simultaneously to both groups. This
included the assessment, outcome measures and the
specific training program. The improvements in exercise
performance for COPD and CHF were similar. Whereas there
is no consensus on the optimal training prescription for
CHF,49 the exercise rehabilitation program adhered to the
international recommendations for COPD.15 Physical
training was individually prescribed, aiming for high inten-
sity from the outset 85% predicted peak VO2, which the
patients with CHF achieved. Improvements in exercise
performance occurred in the first two weeks and were
statistically significant by session seven (halfway). There
were no significant differences in the training profile
between the two groups. The program was predominantly
endurance training, which likely accounts for the very
modest changes in quadriceps strength post exercise.COPD-ER p valueb COPD-ER and CHF-ERc
68 (50e85) <0.001 0.69
348 (249e447) <0.001 1.0
2 (6 to 10) 0.62 0.46
0.94 (0.57e1.31) <0.001 0.32
0.72 0.43
1.24 (0.85e1.64) <0.001 0.001
1.17 0.002
0.92 (0.56e1.30) <0.001 0.047
0.82 0.17
0.78 (0.44e1.12) <0.001 0.84
0.66 0.63
lk Test, PT e peak torque, HRQL e Health related quality of life,
Figure 3 Training Profile of COPD and CHF.
Integrating patients with COPD and heart failure 1479The improvements in health related quality of life, as
measured by a disease specific questionnaire, were
comparable between the groups although there were
slightly lower scores among those with CHF. The education
part of the pulmonary rehabilitation course was primarily
designed for COPD and was not adapted for the trial. Both
groups attended the lectures, and at least half were
generic. This aspect of the program could be modified
further and may enhance the effect on health status. The
more specific aspects of disease management were
addressed predominantly outside of the training program
(all the patients with chronic heart failure were under
a community specialist nurse).
The safety of physical training for patients with CHF has
been a concern and may have limited its practical devel-
opment. In keeping with recent reports, we did not identify
any adverse effects with training.49,50 The number of
patients with CHF who withdrew for clinical reasons was
similar in both the exercise training and the usual care
groups. The only adaptation for the assessment of CHF
patients for exercise rehabilitation was the need to exclude
arrhythmias. For this purpose a full cardiopulmonary exer-
cise test was performed under laboratory conditions
(telemetry during field testing could be used). During the
rehabilitation program cardiac monitoring during exercise
training was not required by either group. This is usual
practice for COPD rehabilitation and has been reported as
a safe approach despite the co-existence of CHF in this
population.45
There were limitations to the study. There was no sham
training in the CHF usual care group. However, no
improvement in exercise performance are seen if exercise
training is excluded from PR in COPD.51 After three baseline
tests, the patients in the CHF-ER group performed three
further ISWTs during the program. As these were not per-
formed by the CHF-UC group, a bias for the CHF-ER group
cannot be completely excluded. However, Lewis et al. have
reported that the mean ISWT distance does not change with
serial tests under controlled conditions.52 The study was
performed in a single centre, hospital outpatient setting,
which limits their generalizeability. Confirmation of effec-
tiveness from other centers is required. Only the short-term
effects are described and strategies for long-term adher-
ence needs further evaluation for both groups.16,22 This
study was conducted to see if combined training was
feasible and effective, further studies would need to bedone to investigate whether combined rehabilitation
provides economies of scale for both populations.
In conclusion, patients with CHF can make significant
improvements in exercise performance and heath status from
an existing pulmonary rehabilitation program and the results
are comparable with COPD. Combined training is feasible
without any negative interaction between the groups. The
provision of exercise rehabilitation needs to be increased for
CHF and for an increasing number of other respiratory
diseases, therefore developing generic symptom based exer-
cise rehabilitation for exertional dyspnea could be a success-
ful strategy. This study highlights the possibility of organising
services for chronic diseasearounda commondisability rather
than the primary organ disease.
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